Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem's Q1 Revenues Dip 1 Percent

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Monday that its first-quarter revenues declined 1 percent year over year as a decline in product revenues was offset by growth for its clinical lab services.

The New York-based provider of research products and molecular biology reagents brought in total revenues of $25.6 million for the three months ended Oct. 31, compared to $25.8 million for the first quarter of Fiscal Year 2012. Its product revenues fell to $8.4 million from $9.7 million, while its clinical lab sales jumped to $15.2 million from $14.2 million. Royalty and license fee income was $2 million versus $1.9 million.

The firm noted that its clinical lab business was negatively impacted by around $700,000 due to Hurricane Sandy, which resulted in sharply diminished specimen counts over the last three days of the quarter.

Enzo posted a net loss of $3.7 million, or $.09 per share, for the quarter, compared to a net loss of $4.5 million, or $.12 per share, for the first quarter of FY 2012.

"We are making noteworthy progress and have yet to fully benefit from the anticipated $6 million in annual cost savings that will result from last year's realignment," Enzo President Barry Weiner said in a statement. "We anticipate that new products, operating efficiencies, enhanced marketing efforts and improved cash utilization will drive stronger operating results as the year develops."

The firm announced during its fourth-quarter conference call in October that it would realign its operations with the aim of reducing its cash burn.

Enzo finished the quarter with $13.4 million in cash, cash equivalents, and short-term investments. It also held working capital of $18.3 million.

Subsequent to the end of its first quarter, Enzo won a patent infringement case against Life Technologies. The jury in that case awarded Enzo $48.6 million in damages, though Life Tech intends to appeal the decision.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.